



**Division de gastro-entérologie
Division of Gastroenterology**

Dr. A. Bitton

Directeur
Director

Dr. W. Afif

Directeur de site, HGM
Site Director, MGH

Dr. V. Baffis

Dr. A. Barkun

Directeur endoscopie
thérapeutique et directeur
de l'évaluation de la qualité,
CUSM

Director, Bilio-Pancreatic
Endoscopy and Chief Quality
Officer, MUHC

Dr. T. Bessissow

Dr. P. Cleland

Dr. M. Deschênes

Directeur de l'hépatologie, CUSM
Hepatology Director, MUHC

Dr. C. A. Fallone

President, Association des médecins
du département, CUSM
Chair, Departmental Association
of Physicians, MUHC

Dr. P. Ghali

Directeur de site, HRV
Site Director, RVH

Dr. S. Mayrand

Directeur, Finances
Financial Director

Dr. S. Mishkin

Dr. P. Lakatos

Directeur, Centre MII, CUSM
Director, MUHC IBD Centre

Dr. J. Parent

Dr. G. Sebastiani

Dr. E. Seidman

Titulaire de la chaire en MII
et directeur de la recherche
McGill Chair in IBD and Director
of G.I. Research

Dr. M. Sewitch

Directrice de la recherche en santé
des populations, CUSM
Director, Population Health Research
MUHC

Dr. C. Soulellis

Directeur de programme
de résidence, Université McGill
Residency Program Director
McGill University

Dr. P.L. Szego

Dr. K. Waschke

Directeur de l'endoscopie, CUSM
Endoscopy Director, MUHC

Dr. G. Wild

Dr. P. Wong

Hôpital général de Montréal
Montreal General Hospital
C7-200 - 1650 Cedar
Montréal QC H3G 1A4
Canada

Tel 514 934-8308

Fax 514 934-8531

Hôpital Royal Victoria, site Glen
Royal Victoria Hospital, Glen site
D05.7150 - 1001 boul Décarie
Montréal QC H4A 3J1
CANADA

Tel 514 843-1616

Fax 514 843-1421

cusc.ca muhc.ca

Response to reviewers

23/09/2019

Subrata Ghosh

Editor-in-Chief

Jin-Zhou Tang

Science Editor, Editorial Office

Dear Editors,

Please find attached our detailed responses to the reviewers' comments:

Title:

Disease monitoring strategies in IBD: what do we mean by 'tight control'?

Authors:

Lorant Gonczi, Talat Bessissow, Peter L. Lakatos

Reviewer #1, Number ID: unknown; review received via email.

This review is well written and is aiming at detailed analysis of recent evidences on treat-to-target approach to target composite clinical and endoscopical therapeutic endpoints. For this aim, close monitoring of objective markers of inflammation (clinical, endoscopical and biomarkers) to direct therapeutic decisions until these goals are reached.

According to this reviewing process there are a lot of successful scientific evidences which support the benefit of 'treat-to-target' and 'tight control' strategies. However, there remain many questions how this approaches are validated using composite definition of endoscopic items and biomarkers as authors have pointed out. These undefined items require resolution by prospective clinical trials which are fitted to real world scenario of treatment courses as is pointed out by authors.



In this review it is required to mention on monitoring process and that TDM should have a great role to analyze treatment failure such as loss of response at a proper timing. When using new biologics in appropriate way early diagnosis of LOR of the first biologic and quick switching to another biologic or to a new drug is warranted. For this switching how TDM should be used? Please give a comment on this issue.

Thank you for the comments, we included a short section and an additional table regarding the role of TDM in LOR.

Reviewer #2, Number ID: 00036225

Thank you for the comments. We included some of the reviewer's suggestions and corrected all orthographic mistakes/typing errors.

Reviewer #3, Number ID: 03373346

No comments were raised.

Reviewer #4, Number ID: 00503405

We corrected the mentioned typing errors.

We further modified and language edited the manuscript, which has been reviewed by a native English-speaking co-author.

Sincerely,

Dr. Lorant Gonczi and Dr. Peter Lakatos on behalf of all the authors,

Peter LAKATOS, MD, DSc, FEBG, AGAF
Associate Editor of World Journal Of Gastroenteorlogy



Director of IBD Centre, Professor of Medicine,
McGill University, MUHC, Montreal General Hospital,
1650 Ave. Cedar, D16.173.1, Montreal, QC, H3G 1A4
Tel: +-1-514-9341934 x ext 45567
Fax: +1-514-934-4452
Tel: +1-514-4317994
e-mail: Peter.Lakatos@muhc.mcgill.ca
e-mail: peter.lakatos@mcgill.ca